<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SYNRIBO- omacetaxine mepesuccinate injection, powder, lyophilized, for solution </strong><br>Cephalon, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. <br>SYNRIBO<span class="Sup">®</span> (omacetaxine mepesuccinate) for injection, for subcutaneous use                                                                                                                                                                                                                                                                       Initial U.S. Approval: 2012</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage (<a href="#i4i_indications_id_90bb20c0-4ea7-4f41-8913-80c4db274411">1</a>) 	02/2014 </p>
<p class="Highlighta">Dosage and Administration (<a href="#i4i_section_id_57207e74-2192-4f80-8111-af9d7694c717">2.4</a>, <a href="#_2.5_Storage_Conditions">2.5</a>, <a href="#ID_769c7898-01c2-4f54-bc96-be7e453f4721">2.6</a>, <a href="#ID_bba368d9-7350-4d68-badf-30bd33a70e34">2.7</a>) 	04/2014 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) (<a href="#i4i_indications_id_90bb20c0-4ea7-4f41-8913-80c4db274411">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Induction Dose: 1.25 mg/m<span class="Sup">2</span> administered by subcutaneous injection twice daily for 14 consecutive days of a 28-day cycle (<a href="#i4i_section_id_a7241c62-781a-417b-adc3-804d10e674f8">2.1</a>).  </dd>
<dt>•</dt>
<dd>Maintenance Dose: 1.25 mg/m<span class="Sup">2</span> administered by subcutaneous injection twice daily for 7 consecutive days of a 28-day cycle (<a href="#i4i_section_id_10de5edf-2e43-4fd9-acd8-c128c7ad8bf3">2.2</a>).  </dd>
<dt>•</dt>
<dd>Dose modifications are needed for toxicity (<a href="#i4i_section_id_7dcce8fc-b120-4e33-a20f-170833c9088a">2.3</a>).  </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single-use vial containing 3.5 mg of omacetaxine mepesuccinate as a lyophilized powder (<a href="#i4i_dosage_form_strength_id_e0ad89f9-81c2-41a1-81b7-0b32a2cdca4f">3</a>).   </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.    (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:  severe and fatal <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.  Monitor hematologic parameters frequently (<a href="#i4i_section_id_7dcce8fc-b120-4e33-a20f-170833c9088a">2.3</a>, <a href="#i4i_section_id_afe0f4f2-642d-49d8-adf5-234efba4ba7b">5.1</a>).  </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.  Fatal <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span> and severe, non-fatal <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (<a href="#i4i_section_id_afe0f4f2-642d-49d8-adf5-234efba4ba7b">5.1</a>, <a href="#i4i_section_id_7a2c26fd-b9e1-417f-a114-bb12d7d5df0e">5.2</a>).  </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>: <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including hyperosmolar non-ketotic <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (<a href="#i4i_section_id_0aa6f5a4-7e54-4b0e-b436-fcfae50cce46">5.3</a>).  </dd>
<dt>•</dt>
<dd>Embryo-fetal toxicity: can cause fetal harm.  Advise females of reproductive potential to avoid pregnancy (<a href="#i4i_section_id_c7ca0332-6410-49fe-8d66-759cc8558399">5.4</a>, <a href="#i4i_pregnancy_id_2174250d-693a-4c1b-bcb3-a5c46a9bc2b3">8.1</a>).  </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">CML-Chronic Phase and Accelerated Phase:  Most common adverse reactions (frequency ≥ 20%): <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> (<a href="#i4i_section_id_4544fe8d-8968-4b33-ac35-543817ed8dfb">6.1</a>).   </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-800-896-5855 or FDA at 1-800-FDA-1088 or</span><span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Induction Schedule</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Maintenance Dosing</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Adjustments and Modifications</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Reconstitution Instructions and Handling Precautions</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Storage Conditions and Storage Time after Preparation of Syringes </a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Considerations for Home Administration</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Disposal and Accidental Spillage Procedures </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Embryo-Fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Additional Data From Safety Population</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Effect of Gender</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.6 Assessment for Risk of QT Prolongation</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Chronic Phase CML (CP CML)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Accelerated Phase CML (AP CML)</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">1<span class="Bold">6</span>.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-20.1" class="toc">Synribo<span class="Sup">TM</span> (Omacetaxine Mepesuccinate) for Injection 3.5 mg/vial, Single-Use Vial Carton Text</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_90bb20c0-4ea7-4f41-8913-80c4db274411"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">SYNRIBO is indicated for the treatment of adult patients with chronic or accelerated phase <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a8d57b96-5138-4139-a269-fc397537a9b9"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7241c62-781a-417b-adc3-804d10e674f8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Induction Schedule</h2>
<p class="First">The recommended starting schedule for induction is 1.25 mg/m<span class="Sup">2</span> administered subcutaneously twice daily at approximately 12 hour intervals for 14 consecutive days every 28 days, over a 28-day cycle.  Cycles should be repeated every 28 days until patients achieve a hematologic response.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10de5edf-2e43-4fd9-acd8-c128c7ad8bf3"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Maintenance Dosing</h2>
<p class="First">The recommended maintenance schedule is 1.25 mg/m<span class="Sup">2</span> administered subcutaneously twice daily approximately 12 hour intervals for 7 consecutive days every 28 days, over a 28-day cycle.  Treatment should continue as long as patients are clinically benefiting from therapy.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7dcce8fc-b120-4e33-a20f-170833c9088a"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Adjustments and Modifications</h2>
<p class="First"><span class="Underline">Hematologic Toxicity:</span></p>
<p>SYNRIBO treatment cycles may be delayed and/or the number of days of dosing during the cycle reduced for hematologic toxicities (e.g. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_afe0f4f2-642d-49d8-adf5-234efba4ba7b">5.1</a>)].  </span></p>
<p>Complete blood counts (CBCs) should be performed weekly during induction and initial maintenance cycles.  After initial maintenance cycles, monitor CBCs every two weeks or as clinically indicated.  If a patient experiences Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count (ANC) less than 0.5 x 10<span class="Sup">9</span>/L) or Grade 3 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet counts less than 50 x 10<span class="Sup">9</span>/L) during a cycle, delay starting the next cycle until ANC is greater than or equal to 1.0 x 10<span class="Sup">9</span>/L and platelet count is greater than or equal to 50 x 10<span class="Sup">9</span>/L.  Also, for the next cycle, reduce the number of dosing days by 2 days (e.g. to 12 or 5 days).  </p>
<p><span class="Underline">Non-Hematologic Toxicity:</span></p>
<p>Manage other clinically significant non-hematologic toxicity symptomatically.  Interrupt and/or delay SYNRIBO until toxicity is resolved.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57207e74-2192-4f80-8111-af9d7694c717"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Reconstitution Instructions and Handling Precautions</h2>
<p class="First">SYNRIBO should be prepared in a healthcare facility and must be reconstituted by a healthcare professional.</p>
<p>Reconstitute SYNRIBO with one mL of 0.9% Sodium Chloride Injection, USP, prior to subcutaneous injection.  After addition of the diluent, gently swirl until a clear solution is obtained.  The lyophilized powder should be completely dissolved in less than one minute.  The resulting solution is clear and colorless and contains 3.5 mg/mL SYNRIBO. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
<p>SYNRIBO does not contain antimicrobial preservatives.  Therefore care must be taken to ensure that the solution for injection is not contaminated during preparation.</p>
<p>SYNRIBO is a cytotoxic drug. Follow special handling and disposal procedures<span class="Sup">1</span>. Wear protective eyewear and gloves during handling and administration of the product.  Proper aseptic technique should be used. Avoid skin and eye contact.  If SYNRIBO comes into contact with skin, immediately and thoroughly wash affected area with soap and water.  If contact with the eyes occurs, thoroughly flush the eyes with water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e8d006c8-d1b1-4260-92e2-41fa959a0c79"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Storage Conditions and Storage Time after Preparation of Syringes </h2>
<p class="First">If SYNRIBO is not used immediately after reconstitution, follow in-use storage conditions and allowable storage times prior to use as instructed in Table 1. Do not administer SYNRIBO outside of the storage conditions and timeframes listed in <a href="#_Ref387389702">Table 1</a>.</p>
<a name="_Ref387389702"></a><table>
<caption><span>Table 1: Storage Conditions and Storage Time after Preparation of Syringes</span></caption>
<col width="58%">
<col width="58%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Storage Conditions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Storage Time</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Room temperature (20°C to 25°C [68°F to 77°F])</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Use within 12 hours of reconstitution</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Refrigerated (2°C to 8°C [36<span class="Sup">o</span>F to 46<span class="Sup">o</span>F])</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Use within 6 days (144 hours) of reconstitution</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_769c7898-01c2-4f54-bc96-be7e453f4721"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Considerations for Home Administration</h2>
<p class="First">Before a decision is made to allow SYNRIBO to be administered by someone other than a healthcare professional, ensure that the patient is an appropriate candidate for self-administration or for administration by a caregiver. Provide training on proper handling, storage conditions, administration, disposal, and clean-up of accidental spillage of the product. Ensure that patients receive the necessary supplies for home administration. At minimum these should include:</p>
<dl>
<dt>•</dt>
<dd>Reconstituted SYNRIBO in syringe with a capped needle for subcutaneous injection.  Syringe(s) should be filled to the patient-specific dose.<dl>
<dt>•</dt>
<dd>Protective eyewear </dd>
</dl>
</dd>
<dt>•</dt>
<dd>Gloves</dd>
<dt>•</dt>
<dd>An appropriate biohazard container</dd>
<dt>•</dt>
<dd>Absorbent pad(s) for placement of administration materials and for accidental spillage</dd>
<dt>•</dt>
<dd>Alcohol swabs</dd>
<dt>•</dt>
<dd>Gauze pads</dd>
<dt>•</dt>
<dd>Ice packs or cooler for transportation of reconstituted SYNRIBO syringes</dd>
</dl>
<p>If a patient or caregiver cannot be trained for any reason, then in such patients, SYNRIBO should be administered by a healthcare professional. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bba368d9-7350-4d68-badf-30bd33a70e34"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Disposal and Accidental Spillage Procedures </h2>
<p class="First">After administration, any unused solution should be discarded properly<span class="Sup">1</span>.  Instruct patients planning home administration on the following: do not recap or clip the used needle, and do not place used needles, syringes, vials, and other used supplies in a household trash or recycling bin.  Used needles, syringes, vials, and other used supplies should be disposed of in an appropriate biohazard container.</p>
<p>If accidental spillage occurs, continue to use protective eyewear and gloves, wipe the spilled liquid with the absorbent pad, and wash the area with water and soap.  Then, place the pad and gloves into the biohazard container and wash hands thoroughly. Return the biohazard container to the clinic or pharmacy for final disposal.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_e0ad89f9-81c2-41a1-81b7-0b32a2cdca4f"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">SYNRIBO for Injection contains 3.5 mg omacetaxine mepesuccinate; as a sterile, preservative-free, white to off-white lyophilized powder in a single-use vial.  </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_a7222b08-49df-4c04-8ec2-737217fb0af1"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_8fc8cc34-12dd-420f-bec4-c484928ba564"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_afe0f4f2-642d-49d8-adf5-234efba4ba7b"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">In uncontrolled trials with SYNRIBO, patients with chronic phase and accelerated phase CML experienced NCI CTC (version 3.0) Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (85%, 88%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (81%, 71%), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (62%, 80%), respectively.  Fatalities related to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurred in 3% of patients in the safety population (N=163).  Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> are at increased risk for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and should be monitored frequently and advised to contact a physician if they have symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.  </p>
<p>Monitor complete blood counts weekly during induction and initial maintenance cycles and every two weeks during later maintenance cycles, as clinically indicated.  In clinical trials <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was generally reversible and usually managed by delaying next cycle and/or reducing days of treatment with SYNRIBO <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_7dcce8fc-b120-4e33-a20f-170833c9088a">2.3</a>) and Adverse Reactions (<a href="#i4i_section_id_4544fe8d-8968-4b33-ac35-543817ed8dfb">6.1</a>)].  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a2c26fd-b9e1-417f-a114-bb12d7d5df0e"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">SYNRIBO causes severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> which increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.  In clinical trials with CP and AP CML patients, a high incidence of Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (85% and 88%, respectively) was observed.  Fatalities from <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span> occurred in 2% of patients treated with SYNRIBO in the safety population.  Severe, non-fatal, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhages</span> occurred in 2% of patients in the same population.  Most <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events were associated with severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.  </p>
<p>Monitor platelet counts as part of the CBC monitoring as recommended <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_afe0f4f2-642d-49d8-adf5-234efba4ba7b">5.1</a>)].</span>  Avoid anticoagulants, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) when the platelet count is less than 50,000/µL as they may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0aa6f5a4-7e54-4b0e-b436-fcfae50cce46"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First">SYNRIBO can induce <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>.  Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> was reported in 11% of patients in the safety population.  Hyperosmolar non-ketotic <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> occurred in 1 patient treated with SYNRIBO in the safety population.  Monitor blood glucose levels frequently, especially in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.  Avoid SYNRIBO in patients with poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus until good glycemic control has been established.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7ca0332-6410-49fe-8d66-759cc8558399"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Embryo-Fetal Toxicity</h2>
<p class="First">SYNRIBO can cause fetal harm when administered to a pregnant woman.  Omacetaxine mepesuccinate caused embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> in animals.  Females of reproductive potential should avoid becoming pregnant while being treated with SYNRIBO.  There are no adequate and well-controlled studies of SYNRIBO in pregnant women.  If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pregnancy_id_2174250d-693a-4c1b-bcb3-a5c46a9bc2b3">8.1</a>)].  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_31104e4b-2c60-4327-bb50-d53658423210"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions have been associated with SYNRIBO in clinical trials and are discussed in greater detail in other sections of the label.  </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span><span class="Italics">  [see Warnings and Precautions (<a href="#i4i_section_id_afe0f4f2-642d-49d8-adf5-234efba4ba7b">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>  <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_7a2c26fd-b9e1-417f-a114-bb12d7d5df0e">5.2</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>  <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_0aa6f5a4-7e54-4b0e-b436-fcfae50cce46">5.3</a>)]</span>
</dd>
</dl>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>The safety data for SYNRIBO are from 3 clinical trials which enrolled a total of 163 adult patients with TKI resistant and/or intolerant chronic phase (N=108) and accelerated phase (N=55) CML.  All patients were treated with initial induction therapy consisting of a dose of 1.25 mg/m<span class="Sup">2</span> administered subcutaneously twice daily for 14 consecutive days every 28 days (induction cycle).  Responding patients were then treated with the same dose and a twice daily schedule for 7 consecutive days every 28 days (maintenance cycle).  </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4544fe8d-8968-4b33-ac35-543817ed8dfb"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Underline">Chronic Phase CML</span></p>
<p>The median duration of exposure for the 108 patients with chronic phase CML was 7.4 months (range 0 to 43 months).  The median total cycles of exposure was 6 (range 1 to 41), and the median total dose delivered during the trials was 131 mg/m<span class="Sup">2 </span>(range 1.2 to 678).  Among the patients with chronic phase CML, 87% received 14 days of treatment during cycle 1.  By cycles 2 and 3, the percentage of patients receiving 14 days of treatment decreased to 42% and 16% respectively.  Of the 91 patients who received at least 2 cycles of treatment, 79 (87%) had at least 1 cycle delay during the trials.  The median number of days of cycle delays was greatest for cycle 2 (17 days) and cycle 3 (25 days) when more patients were receiving induction cycles. </p>
<p>Adverse reactions were reported for 99% of the patients with chronic phase CML.  A total of 18% of patients had adverse reactions leading to withdrawal.  The most frequently occurring adverse reactions leading to discontinuation were <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and increased <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (each 2%).  A total of 87% of patients reported at least 1 Grade 3 or Grade 4 treatment emergent adverse reaction (<a href="#_Ref387145787">Table 2</a>). </p>
<a name="_Ref387145787"></a><table>
<caption><span>Table 2: Adverse Reactions Occurring<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> in at Least 10% of Patients (<span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">Chronic Myeloid Leukemia</span> - Chronic Phase)</span></caption>
<col width="62%">
<col width="15%">
<col width="24%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Occurred in the period between the first dose and 30 days after the last dose.  </dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reaction</span>, injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">injection site hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4316203" conceptname="Injection site hypersensitivity">injection site hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4316211" conceptname="Injection site induration">injection site induration</span>, <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">injection site inflammation</span>, <span class="product-label-link" type="condition" conceptid="4317272" conceptname="Injection site irritation">injection site irritation</span>, <span class="product-label-link" type="condition" conceptid="4317274" conceptname="Injection site mass">injection site mass</span>, <span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">injection site edema</span>, injection site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4318391" conceptname="Injection site dermatitis">injection site rash</span>, and <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> includes bacterial, viral, fungal, and non-specified.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (%) of Patients</span><br><span class="Bold">(N=108)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Adverse reactions</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">All reactions</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 or 4 reactions</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Patients with at least 1 commonly occurring adverse reaction</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First"><span class="Bold">107 (99) </span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">94 (87)</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">82 (76) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">73 (68)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">66 (61) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">39 (36)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">57 (53) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">51 (47)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">18 (17) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">17 (16)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Bone Marrow Failure</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">11 (10) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">11 (10)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">11 (10) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">11 (10)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">44 (41) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">38 (35) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">15 (14) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>/<span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper Abdominal Pain</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">25 (23) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">13 (12) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">31 (29) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">5 (5)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">27 (25) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">25 (23) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema Peripheral</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">17 (16) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd>Infusion and injection site related reactions<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">38 (35)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">52 (48) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">12 (11)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Metabolism and Nutrition Disorders</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">11 (10)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">20 (19) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Extremity</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">14 (13) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">13 (12) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2 (2)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">12 (11)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">22 (20) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">13 (12) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">17 (16) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">18 (17) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">16 (15) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></dd>
</dl></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">12 (11) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>Serious adverse reactions were reported for 51% of patients.  Serious adverse reactions reported for at least 5% of patients were <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">bone marrow failure</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (each 10%), and <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (6%).  Serious adverse reactions of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported for 8% of patients.  </p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> occurred while on study in five (5%) patients with CP CML.  Two patients died due to <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, one due to multi-organ failure, one due to progression of disease, and one from unknown causes.  </p>
<p><span class="Underline">Accelerated Phase CML</span></p>
<p>Median total cycles of exposure was 2 (range 1 to 29), and the median total dose delivered during the trials was 70 mg/m<span class="Sup">2</span>.  The median duration of exposure for the 55 patients with accelerated phase CML was 1.9 months (range 0 to 30 months).  Of the patients with accelerated phase CML, 86% received 14 days of treatment during cycle 1.  By cycles 2 and 3, the percentage of patients receiving 14 days of treatment decreased to 55% and 44% respectively.  Of the 40 patients who received at least 2 cycles of treatment, 27 (68%) had at least 1 cycle delay during the trials.  The median number of days of cycle delays was greatest for cycle 3 (31 days) and cycle 8 (36 days).  </p>
<p>Adverse reactions regardless of investigator attribution were reported for 100% patients with accelerated phase CML.  A total of 33% of patients had adverse reactions leading to withdrawal.  The most frequently occurring adverse reactions leading to withdrawal were <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> (6%), and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (4%).  A total of 84% of patients reported at least 1 Grade 3 or Grade 4 treatment emergent adverse reaction (<a href="#_Ref387146119">Table 3</a>).  </p>
<a name="_Ref387146119"></a><table>
<caption><span>Table 3: Adverse Reactions Occurring<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> in at Least 10% of Patients (<span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">Chronic Myeloid Leukemia</span> - Accelerated Phase)</span></caption>
<col width="62%">
<col width="15%">
<col width="24%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Occurred in the period between the first dose and 30 days after the last dose.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reaction</span>, injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">injection site hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4316203" conceptname="Injection site hypersensitivity">injection site hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4316211" conceptname="Injection site induration">injection site induration</span>, <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">injection site inflammation</span>, <span class="product-label-link" type="condition" conceptid="4317272" conceptname="Injection site irritation">injection site irritation</span>, <span class="product-label-link" type="condition" conceptid="4317274" conceptname="Injection site mass">injection site mass</span>, <span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">injection site edema</span>, injection site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4318391" conceptname="Injection site dermatitis">injection site rash</span>, and <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> includes bacterial, viral, fungal, and non-specified.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (%) of Patients</span><br><span class="Bold">(N=55)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Adverse reactions</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">All reactions</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3 or 4 reactions</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Patients with at least 1 commonly occurring adverse reaction</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First"><span class="Bold">55 (100) </span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">47 (86)</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">28 (51) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">21 (38)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">11 (20) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">9 (16)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">11 (20) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">10 (18)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">32 (58) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">27 (49)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">19 (35) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">4 (7)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">16 (29) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2 (4)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">9 (16) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (2)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>/<span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper Abdominal Pain</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">9 (16) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">17 (31) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">5 (9)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">16 (29) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (2)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">13 (24) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (2)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">7 (13) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd>Infusion and injection site related reactions<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">12 (22)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span><a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">31 (56) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">11 (20)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Metabolism and Nutrition Disorders</span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">7 (13) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (2)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Extremity</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">6 (11) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (2)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">7 (13) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p></td>
<td class="Lrule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">8 (15) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></dd>
</dl></td>
<td class="Lrule" align="center" valign="top"><p class="First">6 (11) </p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1 (2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></dd>
</dl></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6 (11) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 (2)</p></td>
</tr>
</tbody>
</table>
<p>Serious adverse reactions were reported for 60% of patients.  Serious adverse reactions reported for at least 5% of patients were <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (18%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (9%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (7%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6%).  Serious adverse reactions of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported for 11% of patients.  </p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> occurred while on study in 5 (9%) patients with AP CML.  Two patients died due to <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span> and three due to progression of disease.  </p>
<p><span class="Underline">Laboratory Abnormalities in Chronic and Accelerated Phase CML</span></p>
<p>Grade 3/4 laboratory abnormalities reported in patients with chronic and accelerated phase CML are described in <a href="#_Ref387146278">Table 4</a>.  <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> occurred in all patients treated with SYNRIBO <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_afe0f4f2-642d-49d8-adf5-234efba4ba7b">5.1</a>)].</span>  Five patients with chronic phase CML and 4 patients with accelerated phase CML permanently discontinued SYNRIBO due to <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, or bone marrow <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.  An event of hyperosmolar non-ketotic <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> was reported in one patient in the safety population and a similar case has been reported in the literature.  Two patients with chronic phase CML permanently discontinued SYNRIBO due to elevated transaminases.</p>
<a name="_Ref387146278"></a><table>
<caption><span>Table 4: Grade 3/4 Laboratory Abnormalities in Clinical Studies in Patients with Chronic Phase and Accelerated Phase CML</span></caption>
<col width="43%">
<col width="17%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Chronic Phase</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Accelerated Phase</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Bold">Hematology Parameters</span></p></td>
<td class="Lrule Rrule Toprule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin Decreased</span></p></td>
<td class="Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">62</p>
<p>72</p>
</td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">80</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">  Leukocytes Decreased</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">61</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> Decreased</p></td>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top">
<p class="First">81</p>
<p>85</p>
</td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">71</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Platelets Decreased</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">88</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Biochemistry Parameters</span></p></td>
<td class="Lrule Toprule" valign="top"></td>
<td class="Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> (ALT) Increased</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top">
<p class="First">  Bilirubin Increased</p>
<p>  Creatinine Increased</p>
</td>
<td class="Lrule" align="center" valign="top">
<p class="First">9</p>
<p>9</p>
</td>
<td class="Lrule Rrule" align="center" valign="top">
<p class="First">6</p>
<p>16</p>
</td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  Glucose Increased</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">Uric Acid Increased</span></p></td>
<td class="Lrule" align="center" valign="top"><p class="First">56</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">57</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">  Glucose Decreased</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_efc5acbe-c59b-4d8b-9b13-ee7c80d9df90"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Additional Data From Safety Population</h2>
<p class="First">The following adverse reactions were reported in patients in the SYNRIBO clinical studies of patients with chronic phase and accelerated phase CML at a frequency of 1% to less than 10%.  Within each category, adverse reactions are ranked on the basis of frequency.  </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>.</p>
<p><span class="Italics">Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="4096343" conceptname="Bleeding from ear">ear hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation increased</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4330466" conceptname="Bleeding from mouth">mouth hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissure</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4009488" conceptname="Sore gums">gingival pain</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>. </p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, catheter site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, general <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications: </span><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">transfusion reaction</span>.</p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">musculoskeletal chest pain</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="372409" conceptname="Sciatica">sciatica</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. </p>
<p><span class="Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, mental status change.</p>
<p><span class="Italics">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>.</p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>.</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin exfoliation</span>, <span class="product-label-link" type="condition" conceptid="4172432" conceptname="Hyperpigmentation of skin">skin hyperpigmentation</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_82718a84-3ff6-470b-a6c7-5f8dba4e06e5"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Based on the findings from in vitro drug interaction studies with SYNRIBO, no clinical drug interaction trials were warranted <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_38da43d6-1a97-4c04-85a9-59dff90de7d9">12.3</a>)]. </span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_ae1aa526-2a08-4c26-8a57-a236e53a19ca"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2174250d-693a-4c1b-bcb3-a5c46a9bc2b3"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_c7ca0332-6410-49fe-8d66-759cc8558399">5.4</a>)]</span></p>
<p><span class="Italics">Risk Summary</span></p>
<p>Based on its mechanism of action and findings from animal studies, SYNRIBO can cause fetal harm when administered to pregnant women.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.  </p>
<p><span class="Italics">Animal Data</span></p>
<p>In an embryo-fetal development study, pregnant mice were administered omacetaxine mepesuccinate subcutaneously during the period of organogenesis at doses of 0.21 or 0.41 mg/kg/day.  Drug-related adverse effects included embryonic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, an increase in unossified bones/reduced bone ossification and decreased fetal body weights.  Fetal toxicity occurred at doses of 0.41 mg/kg (1.23 mg/m<span class="Sup">2</span>) which is approximately half the recommended daily human dose on a body surface area basis.  </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_2f47f952-32cc-47e5-9f04-c0fd8643b7a9"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether omacetaxine mepesuccinate is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reaction in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.  </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_19b7f505-9400-4e92-bb37-8b76f60ef65c"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of SYNRIBO in pediatric patients have not been established.  </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_c6e3a7e4-fb31-445c-af92-bf3230d94bae"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the chronic and accelerated phase CML efficacy populations 23 (30%) and 16 (46%) patients were ≥65 years of age.  For the age subgroups of &lt;65 years of age and ≥65 years of age, there were differences between the subgroups, with higher rates of major cytogenetic responses (MCyRs) in younger patients with CP CML compared with older patients (23% vs. 9%, respectively) and higher rates of major hematologic responses (MaHRs) in older patients with AP CML compared with younger patients (31% vs. 0%, respectively).  Patients ≥65 years of age were more likely to experience toxicity, most notably hematologic toxicity.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba1df3b2-0fac-47ec-a672-9eb998210665"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No formal studies assessing the impact of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of omacetaxine mepesuccinate have been conducted.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95ecbd13-f3ae-4d80-ae91-6143e0533a45"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No formal studies assessing the impact of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of omacetaxine mepesuccinate have been conducted.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91feac4a-144b-4a26-bbb7-123138d75e8c"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Effect of Gender</h2>
<p class="First">Of the 76 patients included in the chronic phase CML population efficacy analysis, 47 (62%) of the patients were men and 29 (38%) were women.  For patients with chronic phase CML, the MCyR rate in men was higher than in women (21% vs. 14%, respectively).  There were differences noted in the safety profile of omacetaxine mepesuccinate in men and women with chronic phase CML although the small number of patients in each group prevents a definitive assessment.  There were inadequate patient numbers in the accelerated phase subset to draw conclusions regarding a gender effect on efficacy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_3f9d83fb-1717-4a18-826a-71d34908309e"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">A patient in the clinical expanded access program received an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 2.5 mg/m<span class="Sup">2</span> twice daily for 5 days in the 16<span class="Sup">th</span> cycle.  The patient presented with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, gingival <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, and Grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.  When SYNRIBO treatment was temporarily interrupted the <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> and hemorrhagic syndrome resolved, and neutrophil values returned to within normal range.  The <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (Grade 1) improved, and SYNRIBO was restarted.  </p>
<p>No specific antidote for SYNRIBO <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is known. Management of overdosage should include general supportive measures, including monitoring of hematologic parameters.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_e5d5e6e8-3b55-450b-ba58-6c6cbd83f336"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">SYNRIBO contains the active ingredient omacetaxine mepesuccinate, a cephalotaxine ester.  It is a protein synthesis inhibitor.  Omacetaxine mepesuccinate is prepared by a semi-synthetic process from cephalotaxine, an extract from the leaves of <span class="Italics">Cephalotaxus sp</span>.  The chemical name of omacetaxine mepesuccinate is cephalotaxine, 4-methyl (2<span class="Italics">R</span>)-hydroxyl-2-(4-hydroxyl-4-methylpentyl) butanedioate (ester).  </p>
<p>Omacetaxine mepesuccinate has the following chemical structure:  </p>
<div class="Figure">
<a name="id990"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-01.jpg">
</div>
<p>The molecular formula is C<span class="Sub">29</span>H<span class="Sub">39</span>NO<span class="Sub">9</span> with a molecular weight of 545.6 g/mol.  SYNRIBO for Injection is a sterile, preservative-free, white to off-white, lyophilized powder in a single-use vial.  Each vial contains 3.5 mg omacetaxine mepesuccinate and mannitol.  </p>
<p>SYNRIBO is intended for subcutaneous administration after reconstitution with 1.0 mL of 0.9% Sodium Chloride Injection, USP.  The pH of the reconstituted solution is between 5.5 and 7.0.  </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_8b28a0b0-9fce-48b6-911c-9108b6a98469"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_2a90a0c7-07b7-410d-b329-a874e7280b85"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis and is independent of direct Bcr-Abl binding.  Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the large ribosomal subunit from a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of archaeabacteria.  In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr-Abl oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member.  Omacetaxine mepesuccinate showed activity in mouse models of wild-type and T315I mutated Bcr-Abl CML.  </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_38da43d6-1a97-4c04-85a9-59dff90de7d9"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The dose proportionality of omacetaxine mepesuccinate is unknown.  A 90% increase in systemic exposure to omacetaxine mepesuccinate was observed between the first dose and steady state.</p>
<p><span class="Underline">Absorption</span></p>
<p>The absolute bioavailability of omacetaxine mepesuccinate has not been determined.  Omacetaxine mepesuccinate is absorbed following subcutaneous administration, and maximum concentrations are achieved after approximately 30 minutes.  </p>
<p><span class="Underline">Distribution</span></p>
<p>The steady-state (mean ± SD) volume of distribution of omacetaxine mepesuccinate is approximately 141 ± 93.4 L following subcutaneous administration of 1.25 mg/m<span class="Sup">2</span> twice daily for 11 days .  The plasma protein binding of omacetaxine mepesuccinate is less than or equal to 50%.</p>
<p><span class="Underline">Metabolism</span></p>
<p>Omacetaxine mepesuccinate is primarily hydrolyzed to 4′-DMHHT via plasma esterases with little hepatic microsomal oxidative and/or esterase-mediated metabolism in vitro.  </p>
<p><span class="Underline">Elimination</span></p>
<p>The major elimination route of omacetaxine mepesuccinate is unknown.  The mean percentage of omacetaxine mepesuccinate excreted unchanged in the urine is less than 15%.  The mean half-life of omacetaxine mepesuccinate following subcutaneous administration is approximately 6 hours.</p>
<p><span class="Underline">Drug Interactions</span></p>
<p><span class="Italics">Cytochrome P450 Enzymes (CYPs):</span>  Omacetaxine mepesuccinate is not a substrate of CYP450 enzymes in vitro.  Omacetaxine mepesuccinate and 4′-DMHHT do not inhibit major CYPs in vitro at concentrations that can be expected clinically.  The potential for omacetaxine mepesuccinate or 4′-DMHHT to induce CYP450 enzymes has not been determined.</p>
<p><span class="Italics">Transporter Systems: </span> Omacetaxine mepesuccinate is a P-glycoprotein (P-gp) substrate in vitro.  Omacetaxine mepesuccinate and 4′-DMHHT do not inhibit P-gp mediated efflux of loperamide in vitro at concentrations that can be expected clinically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_81d01af5-08cc-4b57-8a3c-8917ae703c6b"></a><a name="section-11.3"></a><p></p>
<h2>12.6 Assessment for Risk of QT Prolongation</h2>
<p class="First">In an uncontrolled pharmacokinetic study there were no reports of QTcF &gt; 480 ms or ΔQTcF &gt; 60 ms in 21 treated patients who received omacetaxine mepesuccinate 1.25 mg/m<span class="Sup">2</span> BID for 14 consecutive days.  There was no evidence for concentration-dependent increases in QTc for omacetaxine mepesuccinate or 4’-DMHHT.  Although the mean effect on QTc was 4.2 ms (upper 95% CI: 9.5 ms), QTc effects less than 10 ms cannot be verified due to the absence of a placebo and positive controls.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_5c5b8973-0e03-48b3-8eff-faf37e8cea9d"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_257c6aa9-550e-450b-ad2c-d388744a111c"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies have been conducted with omacetaxine mepesuccinate.</p>
<p>Omacetaxine mepesuccinate was genotoxic in an in vitro chromosomal aberration test system in Chinese hamster ovary (CHO) cells, but was not mutagenic when tested in an in vitro bacterial cell assay (Ames test), and it did not induce genetic damage using an in vivo mouse micronucleus assay.</p>
<p>SYNRIBO may impair male fertility.  Studies in mice demonstrated adverse effects on male reproductive organs.  Bilateral degeneration of the seminiferous tubular epithelium in testes and hypospermia/<span class="product-label-link" type="condition" conceptid="40492473" conceptname="Aspermia">aspermia</span> in the epididymides were reported in the highest dose group (2.33 mg/kg/day reduced to 1.67 mg/kg/day; 7 to 5 mg/m<span class="Sup">2</span>/day) following subcutaneous injection of omacetaxine mepesuccinate for six cycles over six months.  The doses used in the mice were approximately two to three times the clinical dose (2.5 mg/m<span class="Sup">2</span>/day) based on body surface area.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_28dc3ac2-92e4-40bf-b0e9-9f8fce1f0728"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of SYNRIBO was evaluated using a combined cohort of adult patients with CML from two trials.  The combined cohort consisted of patients who had received 2 or more approved TKIs and had, at a minimum, documented evidence of resistance or intolerance to dasatinib and/or nilotinib.  Resistance was defined as one of the following: no complete hematologic response (CHR) by 12 weeks (whether lost or never achieved); or no cytogenetic response by 24 weeks (i.e., 100% Ph positive [Ph+]) (whether lost or never achieved); or no major cytogenetic response (MCyR) by 52 weeks (i.e., ≥35% Ph+) (whether lost or never achieved); or progressive <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>.  Intolerance was defined as one of the following: 1) Grade 3-4 non-hematologic toxicity that does not resolve with adequate intervention; or 2) Grade 4 hematologic toxicity lasting more than 7 days; or 3) any Grade ≥ 2 toxicity that is unacceptable to the patient.  Patients with NYHA class III or IV heart disease, active <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> or other uncontrolled cardiac conditions were excluded.</p>
<p>Patients were treated with omacetaxine mepesuccinate at a dose of 1.25 mg/m<span class="Sup">2</span> administered subcutaneously twice daily for 14 consecutive days every 28 days (induction cycle).  Responding patients were then treated with the same dose and twice daily schedule for 7 consecutive days every 28 days (maintenance cycle).  Patients were allowed to continue to receive maintenance treatment for up to 24 months.  Responses were adjudicated by an independent Data Monitoring Committee (DMC).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e9df3db-6032-4912-81b1-c74ba63ba7ff"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Chronic Phase CML (CP CML)</h2>
<p class="First">A total of 76 patients with chronic phase CML were included in the efficacy analysis.  The demographics were: median age 59 years, 62% were male, 30% were 65 years of age or older, 80% were Caucasian, 5% were African-American, 4% were Asian and 4% were Hispanic.  Thirty-six (47%) patients had failed treatment with imatinib, dasatinib, and nilotinib.  Most patients had also received prior non-TKI treatments, most commonly hydroxyurea (54%), interferon (30%), and/or cytarabine (29%).  The efficacy endpoint was based on MCyR (adjudicated by a DMC).</p>
<table>
<caption><span>Table 5: Efficacy Results Evaluated by DMC for Patients with CP CML</span></caption>
<col width="31%">
<col width="18%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top"><span class="Italics">Cytogenetic response evaluation is based on standard cytogenetic analysis (at least 20 metaphases).  <br>Complete: 0% Ph+ cells, Partial &gt; 0% to 35% Ph+ cells</span></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Patients</span></p>
<p><span class="Bold"> (N=76)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Primary Response – MCyR</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>Total with MCyR, n (%)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14 (18.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>95% confidence interval</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">(10.5% – 29.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Cytogenetic Response, n (%)</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>Confirmed complete</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6 (7.9)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>Confirmed partial</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (3.9)</p></td>
</tr>
</tbody>
</table>
<p>The mean time to MCyR onset in the 14 patients was 3.5 months.  The median duration of MCyR for the 14 patients was 12.5 months (Kaplan-Meier estimate).  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2f46351b-6e68-418a-b20c-3d3811ad0ec9"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Accelerated Phase CML (AP CML)</h2>
<p class="First">A total of 35 patients with accelerated phase CML were included in the efficacy analysis.   The demographics were: median age was 63 years, 57% were male, 46% were 65 years of age or older, 68% were Caucasian, 23% were African-American, 3% were Asian and 3% were Hispanic.  Twenty-two (63%) of 35 patients with accelerated phase had failed treatment with imatinib, dasatinib, and nilotinib.  Most patients had also received prior non-TKI treatments, most commonly hydroxyurea (43%), interferon (31%), and/or cytarabine (29%).  The efficacy endpoint was assessed based on MCyR and MaHR (complete hematologic response [CHR] or no evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> [NEL]).  The efficacy results for the patients with accelerated phase as adjudicated by the DMC are shown in <a href="#_Ref387146946">Table 6</a>.</p>
<a name="_Ref387146946"></a><table>
<caption><span>Table 6: Efficacy Results Evaluated by DMC for Patients with AP CML</span></caption>
<col width="29%">
<col width="16%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top"><span class="Italics">MaHR is defined as complete hematologic response (CHR) or no evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (NEL): CHR - absolute neutrophil count ≥ 1.5 × 10<span class="Sup">9</span>/liter, platelets ≥ 100 × 10<span class="Sup">9</span>/liter, no blood blasts, bone marrow blasts &lt; 5%, no extramedullary disease; NEL - Morphologic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>-free state, defined as &lt;5% bone marrow blasts.</span></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Patients</span></p>
<p><span class="Bold">(N=35)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Primary Response – MaHR</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>Total with MaHR, n (%)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5 (14.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>95% confidence interval</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">(4.5% - 30.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>CHR</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4 (11.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>NEL</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 (2.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Primary Response – MCyR</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd>Total with MCyR, n (%)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>The mean time to response onset in the 5 patients was 2.3 months.  The median duration of MaHR for the 5 patients was 4.7 months (Kaplan-Meier estimate).  </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_dbd22be4-36ff-4d34-9f14-923568b7c314"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>OSHA Hazardous Drugs. <span class="Italics">OSHA</span>. <a href="http://www.osha.gov/SLTC/hazardousdrugs/index.html">http://www.osha.gov/SLTC/hazardousdrugs/index.html</a>.  </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d0cb81e6-b732-47d3-979c-ae786a28c08d"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a1968344-5b7e-4fbf-a4ce-3600116d2f40"></a><a name="section-15.1"></a><p></p>
<h2>1<span class="Bold">6</span>.1 How Supplied</h2>
<p class="First">SYNRIBO (omacetaxine mepesuccinate) for Injection is supplied in 8 mL clear glass single-use vial in individual cartons.  Each vial contains 3.5 mg of SYNRIBO (omacetaxine mepesuccinate) for Injection (NDC 63459-177-14). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2ceeee3-0c20-46ac-9af2-f56f9df82e50"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store unopened vials at 20<span class="Sup">o</span>C to 25ºC (68<span class="Sup">o </span>F to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature].  Prior to re-constitution, keep product in carton to protect from light.  </p>
<p>Omacetaxine mepesuccinate is a cytotoxic drug.  Follow special handling and disposal procedures<span class="Sup">1</span>.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ec6f6a1c-47da-4f05-9ba7-7fd257dab523"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Underline">Availability of Medication Guide and Instructions for Use </span></p>
<p>Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).  Assist patients and caregivers in understanding their contents and give them the opportunity to discuss the contents of the Medication Guide and Instructions for Use and to obtain answers to any questions they may have prior to initiating therapy.  The complete text of the Medication Guide and Instructions for Use are attached to the prescribing information.</p>
<p><span class="Underline">Patient Training</span></p>
<p>Once it is determined that a patient is an appropriate candidate for self-administration or administration by a caregiver, ensure that patients receive the necessary supplies for home administration of SYNRIBO and train them on the following <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_57207e74-2192-4f80-8111-af9d7694c717">2.4</a>, <a href="#ID_e8d006c8-d1b1-4260-92e2-41fa959a0c79">2.5</a>, <a href="#ID_769c7898-01c2-4f54-bc96-be7e453f4721">2.6</a>, <a href="#ID_bba368d9-7350-4d68-badf-30bd33a70e34">2.7</a>)]:</span></p>
<dl>
<dt>•</dt>
<dd>How to transport reconstituted SYNRIBO in a secure container or packaging and under recommended temperature conditions</dd>
<dt>•</dt>
<dd>Acceptable storage conditions and use times for reconstituted SYNRIBO<dl>
<dt>o</dt>
<dd>When stored in a refrigerator (2°C to 8°C [36°F to 46°F]), use within 6 days (144 hours)</dd>
<dt>o</dt>
<dd>When stored at room temperature (not to exceed 25°C [77°F]), use within 12 hours</dd>
</dl>
</dd>
<dt>•</dt>
<dd>If stored in a refrigerator, keep SYNRIBO from coming into contact with food or drink.</dd>
<dt>•</dt>
<dd>To wear disposable gloves and protective eyewear when handling SYNRIBO.</dd>
<dt>•</dt>
<dd>To wash hands before putting on gloves and after removing gloves.</dd>
<dt>•</dt>
<dd>Not to eat or drink while handling SYNRIBO.  To administer SYNRIBO in an area away from food or food preparation areas.</dd>
<dt>•</dt>
<dd>To administer SYNRIBO in a location away from children and pregnant women.</dd>
<dt>•</dt>
<dd>Proper subcutaneous injection technique including acceptable sites.</dd>
<dt>•</dt>
<dd>The importance of body site selection for administering the injection, as well as the importance of alternating the injection sites.  Advise patients to not inject SYNRIBO into areas of the skin that are tender, red, bruised, hard, or that have <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span> or stretch marks.</dd>
<dt>•</dt>
<dd>In the case of a missed dose: If a patient misses an injection, skip the missed dose and the patient should give the next scheduled injection at the next scheduled time.  Inform patients NOT to give two injections to make up for a missed injection.</dd>
<dt>•</dt>
<dd>In the case that SYNRIBO comes into contact with a patient’s skin or eyes: Advise patients to wash exposed skin with soap and water and in the case of eye exposure, thoroughly flush the eye with water.  After washing or <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, advise patients to call their healthcare provider immediately.</dd>
<dt>•</dt>
<dd>In the case that too much SYNRIBO is injected or that SYNRIBO is accidentally swallowed: Instruct patients to contact their healthcare provider immediately if they have injected too much SYNRIBO, or if someone has swallowed SYNRIBO.</dd>
<dt>•</dt>
<dd>Disposal procedures, including use of an appropriate biohazard container and return of the container to the clinic or pharmacy for final disposal.  Inform patients NOT to recap or clip the used needle and not to place used needles, syringes, vials, and other used supplies in a household trash or recycle container. </dd>
<dt>•</dt>
<dd>Accidental spillage procedures, including wiping the spilled liquid with the absorbent pad (using protective eyewear and gloves), washing the area with water and soap, and proper disposal of materials.</dd>
</dl>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<p>Advise patients of the possibility of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> due to low platelet counts.  Instruct patients to report immediately any signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood in urine</span> or stool; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, or altered vision).  Instruct patients to report in advance if they plan to have any dental or surgical procedures.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> </span></p>
<p>Advise patients of the likelihood that SYNRIBO will cause a decrease in white blood cells, platelets, and red blood cells and that monitoring of these parameters will be needed.  Instruct patients to contact a health care professional if they develop a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs/symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, significant <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></span></p>
<p>Advise patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> of the possibility of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and the need for careful monitoring of blood glucose levels.  Patients with poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus should not be treated with omacetaxine mepesuccinate until good glycemic control has been established.  </p>
<p><span class="Underline">Pregnancy and Nursing</span></p>
<p>Advise patients that omacetaxine mepesuccinate can cause fetal harm when administered to a pregnant woman.  Advise females of reproductive potential of the potential hazard to the fetus and to avoid becoming pregnant.  Advise females to avoid nursing while receiving SYNRIBO.  </p>
<p><span class="Underline">Gastrointestinal Distress</span></p>
<p>Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  If these symptoms persist, they should seek medical attention.  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></span></p>
<p>Advise patients that SYNRIBO may cause <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> and to avoid driving any vehicle or operating any dangerous tools or machinery if they experience this side effect.  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></p>
<p>Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.  Advise patients to immediately report severe or worsening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></span></p>
<p>Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>. </p>
<p>SYN-003</p>
<div class="Figure">
<a name="id1184"></a><img alt="Teva Oncology Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-02.jpg">
</div>
<p><span class="Bold">Distributed by: </span></p>
<p>Teva Pharmaceuticals USA, Inc.</p>
<p>North Wales, PA  19454</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_309bacd4-6d03-4378-81cc-459bc3fc1a1c"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">SYNRIBO<span class="Sup">® </span>(sin-RYE-bo) <br>(omacetaxine mepesuccinate) <br>for injection, for subcutaneous use</span></p>
<p>Read this Medication Guide before you start using SYNRIBO and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. </p>
<p><span class="Bold">What is the most important information I should know about SYNRIBO?</span></p>
<p><span class="Bold">SYNRIBO can cause serious side effects including:</span></p>
<p><span class="Bold">Low blood counts. </span>Low blood counts are common when using SYNRIBO, including low red blood cells, white blood cells, and platelets, and can be severe. If your white blood cell count becomes very low, you are at increased risk for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> which can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your healthcare provider will check your blood counts regularly during treatment with SYNRIBO. Tell your healthcare provider right away if you get any of the following symptoms:</p>
<table>
<col width="58%">
<col width="58%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>feeling very tired</dd>
</dl></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>•</dt>
<dd>body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see below)</dd>
</dl></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>.</span> SYNRIBO causes severe low platelet counts that may increase your risk of severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Severe low platelet counts can cause you to have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in your brain or severe stomach <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your healthcare provider will check your platelet counts regularly during treatment with SYNRIBO. Tell your healthcare provider right away if you get any of the following symptoms:</p>
<table>
<col width="58%">
<col width="58%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>•</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
</dl></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>•</dt>
<dd>easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood in urine</span> or stool</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>vision changes</dd>
</dl></td>
</tr>
</tbody>
</table>
<p>See<span class="Bold"> “What are the possible side effects of SYNRIBO?? </span>for more information about side effects.</p>
<p><span class="Bold">What is SYNRIBO?</span></p>
<p>SYNRIBO is a prescription medicine used to treat adults with a type of blood cancer (<span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>) called <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span> (CML):</p>
<dl>
<dt>•</dt>
<dd>that is in the chronic phase or accelerated phase, and </dd>
<dt>•</dt>
<dd>who have not responded to (resistant) or cannot tolerate 2 or more medicines called tyrosine kinase inhibitors. </dd>
</dl>
<p>It is not known if SYNRIBO is safe and effective in children. </p>
<p><span class="Bold">What should I tell my healthcare provider before using SYNRIBO?</span></p>
<p><span class="Bold">Before using SYNRIBO, tell your healthcare provider if you:  </span></p>
<dl>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or a family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</dd>
<dt>•</dt>
<dd>plan to have any dental or surgical procedures</dd>
<dt>•</dt>
<dd>have any other medical problems</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant.<span class="Bold"></span>SYNRIBO can harm your unborn baby. You should not become pregnant during treatment with SYNRIBO. Tell your healthcare provider right away if you become pregnant during treatment with SYNRIBO.</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if SYNRIBO passes into your breast milk. You and your healthcare provider should decide if you will take SYNRIBO or breastfeed. You should not do both.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.  </p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use SYNRIBO?</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Follow the detailed Instructions for Use at the end of this Medication Guide for information about the right way to:</span><dl>
<dt>o</dt>
<dd><span class="Bold">properly handle and inject SYNRIBO</span></dd>
<dt>o</dt>
<dd><span class="Bold">dispose of used supplies for injecting SYNRIBO</span></dd>
<dt>o</dt>
<dd><span class="Bold">clean up any spilled SYNRIBO</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>Your healthcare provider will tell you how much SYNRIBO to inject and the timing of when to inject it. Inject SYNRIBO exactly as prescribed. </dd>
<dt>•</dt>
<dd>Do not change your dose or the timing of when you inject SYNRIBO, unless your healthcare provider tells you to.</dd>
<dt>•</dt>
<dd>SYNRIBO is given as an injection under the skin (subcutaneous injection) of your thigh or stomach-area (abdomen). The injection can be given in the back of the arm if a caregiver is giving the injection.</dd>
<dt>•</dt>
<dd>If your healthcare provider decides that you or a caregiver can inject SYNRIBO, your healthcare provider will show you or your caregiver how to prepare for an injection and how to inject SYNRIBO before you use it for the first time.  </dd>
<dt>•</dt>
<dd>SYNRIBO is injected 2 times each day, about every 12 hours. </dd>
<dt>•</dt>
<dd>Your healthcare provider may tell you to stop using SYNRIBO for a period of time, or tell you to use SYNRIBO less often depending on the side effects that you get.</dd>
<dt>•</dt>
<dd>Your healthcare provider will arrange for you to receive syringes filled with SYNRIBO that are ready to inject, along with the other supplies that you will need to inject SYNRIBO. Each syringe contains <span class="Bold">1</span> dose of SYNRIBO as prescribed by your healthcare provider.</dd>
<dt>•</dt>
<dd>Follow your healthcare provider’s instructions for how to carry (transport) SYNRIBO using ice packs or a cooler. </dd>
<dt>•</dt>
<dd>Do not eat or drink while handling SYNRIBO.  </dd>
<dt>•</dt>
<dd>You or your caregiver should wear gloves and protective eyewear, for example protective eyeglasses (not regular eyeglasses) or face shield when handling SYNRIBO and while giving your injection.  </dd>
<dt>•</dt>
<dd>If you or your caregiver get SYNRIBO on your skin, wash the area with soap and water.</dd>
<dt>•</dt>
<dd>If you or your caregiver get SYNRIBO in your eyes, flush your eyes with water and call your healthcare provider right away.</dd>
<dt>•</dt>
<dd>If you miss a dose of SYNRIBO, just skip the missed dose. Give your next injection of SYNRIBO at your next scheduled time. Do not give 2 doses of SYNRIBO at the same time to make up for a missed dose.</dd>
<dt>•</dt>
<dd>If you inject too much SYNRIBO, call your healthcare provider or go to the nearest emergency room right away. Follow your healthcare provider’s instructions for when you should inject your next dose of SYNRIBO. </dd>
<dt>•</dt>
<dd>If another person accidentally injects themself with SYNRIBO, or if anyone accidentally swallows SYNRIBO, call your doctor or get emergency help right away.  </dd>
</dl>
<p><span class="Bold">What should I avoid while using SYNRIBO?</span></p>
<p>SYNRIBO may cause <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>. Avoid driving, or operating dangerous tools or machinery if you develop <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> when using SYNRIBO.</p>
<p><span class="Bold">What are the possible side effects of SYNRIBO?</span></p>
<p><span class="Bold">SYNRIBO may cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd>See “<span class="Bold">What is the most important information I should know about SYNRIBO?</span>?</dd>
<dt>•</dt>
<dd>
<span class="Bold">High blood sugar levels (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>).</span> SYNRIBO can cause high blood sugar levels. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or are at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, your healthcare provider will check your blood glucose levels often during treatment with SYNRIBO. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or if your blood sugar is not well controlled, your healthcare provider may decide not to start treatment with SYNRIBO until your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> is under control first.</dd>
</dl>
<p>The most common side effects of SYNRIBO are:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>. See the information about low blood cell counts in the section “<span class="Bold">What is the most important information I should know about SYNRIBO??</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection site</dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all of the side effects of SYNRIBO. For more information, ask your healthcare provider or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store SYNRIBO?</span></p>
<dl>
<dt>•</dt>
<dd>Carry (transport) SYNRIBO as instructed by your healthcare provider.  It is important to use ice packs or a cooler. </dd>
<dt>•</dt>
<dd>When stored in a refrigerator 36°F to 46°F (2°C to 8°C), <span class="Bold">use SYNRIBO</span><span class="Bold">within 6 days from when it was mixed</span>.</dd>
<dt>•</dt>
<dd>When stored at room temperature, 68°F to 77°F (20°C to 25°C), <span class="Bold">use SYNRIBO within 12 hours from when it was mixed</span>.</dd>
<dt>•</dt>
<dd>When stored in a refrigerator, keep SYNRIBO from coming into contact with food or drink</dd>
</dl>
<p><span class="Bold">Keep SYNRIBO and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of SYNRIBO.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SYNRIBO for a condition for which it was not prescribed. Do not give SYNRIBO to other people even if they have the same symptoms you have. It may harm them.</p>
<p>If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about SYNRIBO that is written for health professionals.</p>
<p>For more information, go to <a href="http://www.synribo.com">www.synribo.com</a> or call Teva at 1-800-896-5855.</p>
<p><span class="Bold">What are the ingredients in SYNRIBO?</span></p>
<p>Active ingredient: omacetaxine mepesuccinate</p>
<p>Inactive ingredients: mannitol</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Distributed by:</span></p>
<div class="Figure">
<a name="id1288509956"></a><img alt="Teva oncology logo 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-03.jpg">
</div>
<p>Teva Pharmaceuticals USA, Inc.</p>
<p>North Wales, PA  19454</p>
<p>SYNMG-001</p>
<p>Issued: April 2014</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="ID_2ebfa570-8180-466a-b277-42b07ceec9ed"></a><a name="section-18"></a><p></p>
<h1>Instructions for Use</h1>
<p class="First"><span class="Bold">SYNRIBO<span class="Sup">® </span>(sin-RYE-bo) <br>(omacetaxine mepesuccinate) <br>for injection, for subcutaneous use</span></p>
<p>Read this Instructions for Use before you inject SYNRIBO for the first time and each time you get a refill. Also read the Medication Guide for SYNRIBO. Before you or your caregiver injects SYNRIBO, your healthcare provider will show you how to: </p>
<dl>
<dt></dt>
<dd><dl>
<dt>•</dt>
<dd>properly handle and inject SYNRIBO</dd>
<dt>•</dt>
<dd>dispose of used supplies for injecting SYNRIBO</dd>
<dt>•</dt>
<dd>clean up any spilled SYNRIBO</dd>
</dl></dd>
</dl>
<p><span class="Bold">Important:</span></p>
<dl>
<dt>•</dt>
<dd>Be sure that you store SYNRIBO exactly as your healthcare provider tells you to. See the section “<span class="Bold">How should I store SYNRIBO?</span>? in the Medication Guide. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Never try to re-cap the needle</span>. This could cause a needle-stick injury.</dd>
<dt>•</dt>
<dd>If SYNRIBO comes into contact with your skin, wash the area well with soap and water.</dd>
</dl>
<p>Your healthcare provider will arrange for you to receive all of the supplies that you will need for each injection of SYNRIBO:</p>
<dl>
<dt>•</dt>
<dd>syringe with attached needle, containing SYNRIBO for injection</dd>
<dt>•</dt>
<dd>protective eyewear, such as protective eyeglasses (not regular eyeglasses) or face shield</dd>
<dt>•</dt>
<dd>gloves</dd>
<dt>•</dt>
<dd>disposal biohazard container</dd>
<dt>•</dt>
<dd>absorbent pads for use to clean up an accidental spill of SYNRIBO</dd>
<dt>•</dt>
<dd>alcohol swabs</dd>
<dt>•</dt>
<dd>gauze pads</dd>
</dl>
<p>You may also need an adhesive bandage.</p>
<p><span class="Bold">Step 1</span>.  Preparing to give an injection of SYNRIBO.</p>
<dl>
<dt>•</dt>
<dd>Find a clean flat work surface.  </dd>
<dt>•</dt>
<dd>Wash your hands well with soap and water. </dd>
<dt>•</dt>
<dd>Put on a pair of gloves and your protective eyewear before you handle the syringe containing SYNRIBO.</dd>
<dt>•</dt>
<dd>Gather the rest of your supplies and place them on your work surface.</dd>
</dl>
<p><span class="Bold">Step 2</span>.  Choose an injection site.</p>
<dl>
<dt>•</dt>
<dd>You may inject SYNRIBO into your thigh or stomach-area (abdomen). See Figure A. The injection can be given in the back of your arm if a caregiver is giving the injection. See Figure B.  </dd>
<dt>•</dt>
<dd>Use a different site for each injection to help decrease <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> at the injection site. Each injection site should be at least 1 inch away from any recently used injection site.</dd>
<dt>•</dt>
<dd>Do not inject SYNRIBO into areas of your skin that are tender, red, bruised, hard, or that have <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span> or stretch marks.</dd>
</dl>
<p><span class="Bold">Figure A	   Figure B</span></p>
<span class="Bold"><div class="Figure">
<a name="id1288517138"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-04.jpg">
</div></span><span class="Bold"><div class="Figure">
<a name="id1288517763"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-05.jpg">
</div></span><p><span class="Bold">Step 3. </span>Prepare the injection site.</p>
<dl>
<dt>•</dt>
<dd>Clean the injection site well with an alcohol wipe and allow it to air dry. See Figure C.</dd>
</dl>
<p><span class="Bold">Figure C</span></p>
<span class="Bold"><div class="Figure">
<a name="id1288517219"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-06.jpg">
</div></span><p><span class="Bold">Step 4</span>. Inject SYNRIBO.</p>
<dl>
<dt>•</dt>
<dd>Carefully remove the needle cap by pulling, taking care not to stick yourself. See Figure D.  </dd>
<dt>•</dt>
<dd>Do not press down on the plunger.</dd>
</dl>
<p><span class="Bold">Figure D</span></p>
<span class="Bold"><div class="Figure">
<a name="id1288517257"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-07.jpg">
</div></span><dl>
<dt>•</dt>
<dd>With one hand, pinch skin of injection site between your thumb and forefinger. See Figure E.</dd>
</dl>
<p><span class="Bold">Figure E</span></p>
<span class="Bold"><div class="Figure">
<a name="id1288517305"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-08.jpg">
</div></span><dl>
<dt>•</dt>
<dd>With your other hand, hold the syringe<span class="Italics"></span>at a 45 degree or 90 degree angle to your skin. Use a quick dart-like motion to insert the needle through the skin at the injection site. See Figures F and G. The needle should go through the skin but not into your muscle.</dd>
</dl>
<p><span class="Bold">Figure F	   Figure G</span></p>
<span class="Bold"><div class="Figure">
<a name="id1288518933"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-09.jpg">
</div></span><span class="Bold"><div class="Figure">
<a name="id1288518959"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-10.jpg">
</div></span><dl>
<dt>•</dt>
<dd>Slowly push down on the plunger with your thumb until syringe is empty. See Figure H.</dd>
</dl>
<p><span class="Bold">Figure H</span></p>
<span class="Bold"><div class="Figure">
<a name="id1288520387"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-11.jpg">
</div></span><dl>
<dt>•</dt>
<dd>Stop pinching your skin. Quickly remove needle and then apply pressure on injection site with a dry gauze pad. You can put a small adhesive bandage over the injection site if there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. See Figure I.</dd>
</dl>
<p><span class="Bold">Figure I</span></p>
<span class="Bold"><div class="Figure">
<a name="id1288521255"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-12.jpg">
</div></span><dl>
<dt>•</dt>
<dd>Follow the instructions below for how to dispose of the syringe, needle, and other supplies used to give your injection.</dd>
<dt>•</dt>
<dd>Remove your gloves. Wash your hands right away with soap and water, and then remove your protective eyewear.</dd>
</dl>
<p><span class="Bold">How should I throw away (dispose of) used SYNRIBO syringes, needles, and other supplies?</span></p>
<dl>
<dt>•</dt>
<dd>Throw away (dispose of) used SYNRIBO syringes, needles, and other used supplies in an appropriate biohazard container.</dd>
<dt>•</dt>
<dd>Return the biohazard container to your healthcare provider for disposal. </dd>
<dt>•</dt>
<dd>Do not place used syringes, needles, or other supplies in a household trash or recycle container. Do not recap or clip the used needle. </dd>
<dt>•</dt>
<dd>Do not throw away the protective eyewear. You will need them for each dose of SYNRIBO.</dd>
</dl>
<p><span class="Bold">What should I do in case of an accidental SYNRIBO spill?</span></p>
<dl>
<dt>•</dt>
<dd>Your healthcare provider will arrange for you to receive supplies to use in case you spill SYNRIBO. </dd>
<dt>•</dt>
<dd>Follow your healthcare provider’s instructions about how to clean up a SYNRIBO spill.</dd>
<dt>•</dt>
<dd>Do not touch a spill unless you are wearing gloves and protective eyewear. </dd>
<dt>•</dt>
<dd>Use an absorbent pad to wipe up the spill. Wash the area with soap and water. Use an extra absorbent pad or paper towel to dry the area.</dd>
<dt>•</dt>
<dd>Place the pad, gloves, and other supplies that were used to clean the spill in the biohazard container.  </dd>
<dt>•</dt>
<dd>Call your healthcare provider right away to report the spill.  </dd>
</dl>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Distributed by:</span></p>
<div class="Figure">
<a name="id1377514233"></a><img alt="Teva Oncology logo 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-13.jpg">
</div>
<p>Teva Pharmaceuticals USA, Inc.</p>
<p>North Wales, PA  19454</p>
<p>SYNIFU-001</p>
<p>Issued: April 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7e6057d7-ec70-4214-8cec-a6126dd3806e"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel, Part 1 of 2</h1>
<div class="Figure">
<a name="id1288511286"></a><img alt="Synribo¬&lt;sup&gt;¬TM¬&lt;/sup&gt;¬ (Omacetaxine Mepesuccinate) for Injection 3.5 mg/vial, Single-Use Vial Carton, Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-14.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_896830f5-d885-41b2-9999-584f215b93c6"></a><a name="section-20"></a><p></p>
<h1>Package/Label Display Panel, Part 2 of 2</h1>
<div class="Figure">
<a name="id1288504374"></a><img alt="Synribo¬&lt;sup&gt;¬TM¬&lt;/sup&gt;¬ (Omacetaxine Mepesuccinate) for Injection 3.5 mg/vial, Single-Use Vial Carton, Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83a504ef-cf92-467d-9ecf-d251194a3484&amp;name=bcd20457-429a-4a01-9fd2-6e5743d6f44a-15.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3259cab5-b03d-47ce-b380-ae2a5551e013"></a><a name="section-20.1"></a><p></p>
<h2>Synribo<span class="Sup">TM</span> (Omacetaxine Mepesuccinate) for Injection 3.5 mg/vial, Single-Use Vial Carton Text</h2>
<p class="First"><span class="Bold">NDC</span> 63459-177-14<span class="Bold">                          Rx only</span></p>
<p><span class="Bold">Single-Use Vial.</span><br><span class="Bold">Discard unused portion.</span></p>
<p><span class="Bold">Synribo<span class="Sup">TM</span></span><br><span class="Bold">(omacetaxine mepesuccinate)</span><br><span class="Bold">for Injection</span></p>
<p><span class="Bold">3.5 mg/vial</span></p>
<p><span class="Bold">For Subcutaneous Use Only</span><br><span class="Bold">Must be Reconstituted Before Use</span></p>
<p><span class="Bold">Distributed by:</span><br>Teva Pharmaceuticals USA, Inc.<br>North Wales, PA 19454</p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SYNRIBO 		
					</strong><br><span class="contentTableReg">omacetaxine mepesuccinate injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63459-177</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OMACETAXINE MEPESUCCINATE</strong> (OMACETAXINE) </td>
<td class="formItem">OMACETAXINE MEPESUCCINATE</td>
<td class="formItem">3.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63459-177-14</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203585</td>
<td class="formItem">11/19/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cephalon, Inc.
							(183236314)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bcd20457-429a-4a01-9fd2-6e5743d6f44a</div>
<div>Set id: 83a504ef-cf92-467d-9ecf-d251194a3484</div>
<div>Version: 3</div>
<div>Effective Time: 20140514</div>
</div>
</div> <div class="DistributorName">Cephalon, Inc.</div></p>
</body></html>
